About sotrovimab
Monoclonal antibody antiviral
Used for
- Treatment of mild-to-moderate COVID-19 in eligible high-risk patients, where susceptible variants circulate.
Usual adult dose
500 mg once as an intravenous infusion over 30 minutes, given early in illness.
Usual dose in children
For eligible patients aged 12 years or older and weighing at least 40 kg: 500 mg once intravenously.
Common side effects
- Infusion-related reactions
- Diarrhea
- Rash
- Nausea
Important warnings
- Use depends on circulating variants; resistance can reduce effectiveness.
- Infusion reactions, including severe allergic reactions, can occur during or after treatment.
- Not authorized for patients hospitalized because of COVID-19 or requiring oxygen due to COVID-19.
- Benefit is greatest when treatment begins early after symptoms start.
Pregnancy
Human pregnancy data are limited. Use only when potential benefit outweighs potential risk.
Breastfeeding
It is unknown whether sotrovimab passes into breast milk; effects on infants are uncertain.
Interactions
- No clinically significant drug interactions are known.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.